Advertisement

Tumor Biology

, Volume 36, Issue 4, pp 2983–2992 | Cite as

Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma

  • Rong-Rong Song
  • Xiao-Lin Gu
Research Article

Abstract

The aim of the meta-analysis described below was to investigate the correlation between serum levels of adiponectin (ADPN) and the pathogenesis of hepatocellular carcinoma (HCC). Relevant studies about serum ADPN levels and the pathogenesis of HCC were identified by searching electric databases and by manual search. The included studies were selected in strict accordance with the inclusion and exclusion criteria. Detailed criteria were described in “Materials and methods” section. Statistical analyses were conducted with the STATA 12.0 statistical software (StataCorp, College Station, TX, USA). A total of nine studies were incorporated into this meta-analysis after careful consideration, including 705 HCC patients and 1390 healthy controls. This meta-analysis demonstrated that the serum ADPN levels in HCC patients were significantly higher than those in healthy controls (standard mean difference (SMD) = 0.97, 95 % confidence intervals (CI) = 0.02∼1.93, P < 0.05). The result of subgroup analysis by ethnicity revealed that serum ADPN levels in Caucasians and Asians were both obviously higher than those in healthy controls (Caucasians: SMD = 0.51, 95 % CI = 0.30∼0.73, P < 0.001; Asians: SMD = 0.49, 95 % CI = 0.06∼0.91, P < 0.05), but in Africans, the differences between HCC patients and controls had no statistical significance (SMD = 2.64, 95 % CI = −3.01∼8.30, P = 0.36). The evidence obtained by this meta-analysis suggests that serum ADPN levels are associated with the pathogenesis of HCC. Further conclusion might be that increased serum levels of ADPN can inhibit tumor growth and play a protective role in the development of HCC.

Keywords

Serum adiponectin levels Hepatocellular carcinoma Meta-analysis 

Notes

Acknowledgments

We would like to acknowledge the reviewers for their useful comments on this paper.

Conflicts of interest

None

References

  1. 1.
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73. e1.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Blum HE. Hepatocellular carcinoma: HCC. Hepat Mon. 2011;11(2):69–70.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;67(2):315–24.CrossRefPubMedGoogle Scholar
  4. 4.
    Bovio G, Fonte ML, Baiardi P. Prevalence of upper gastrointestinal symptoms and their influence on nutritional state and performance status in patients with different primary tumors receiving palliative care. Am J Hosp Palliat Care. 2014;31(1):20–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Jiang GQ, Qian JJ, Yao J, Jin SJ, Bai DS. Acute pancreatitis and obstructive jaundice as initial complaints of hepatocellular carcinoma: case report. World J Surg Oncol. 2014;12:13.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.CrossRefPubMedGoogle Scholar
  7. 7.
    Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med. 2007;120(3):194–202.CrossRefPubMedGoogle Scholar
  8. 8.
    Wang SN, Lee KT, Ker CG. Leptin in hepatocellular carcinoma. World J Gastroenterol. 2010;16(46):5801–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011;17(23):2801–11.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Uribe M, Zamora-Valdes D, Moreno-Portillo M, Bermejo-Martinez L, Pichardo-Bahena R, Baptista-Gonzalez HA, et al. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann Hepatol. 2008;7(1):67–71.PubMedGoogle Scholar
  11. 11.
    Fukushima N, Kuromatsu R, Arinaga-Hino T, Ando E, Takata A, Sumie S, et al. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol Res. 2010;40(9):911–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Kotani K, Wakai K, Shibata A, Fujita Y, Ogimoto I, Naito M, et al. Serum adiponectin multimer complexes and liver cancer risk in a large cohort study in Japan. Asian Pac J Cancer Prev. 2009;10 Suppl:87–90.Google Scholar
  13. 13.
    Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond). 2010;119(10):431–6.CrossRefGoogle Scholar
  14. 14.
    Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013;19(8):1926–32.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Shin E, Yu YD, Kim DS, Won NH. Adiponectin receptor expression predicts favorable prognosis in cases of hepatocellular carcinoma. Pathol Oncol Res. 2014;20(3):667–75.CrossRefPubMedGoogle Scholar
  16. 16.
    Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine. 2010;37(1):11–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol. 2010;24(7):1441–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Byeon JS, Jeong JY, Kim MJ, Lee SM, Nam WH, Myung SJ, et al. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer. 2010;127(12):2758–67.CrossRefPubMedGoogle Scholar
  19. 19.
    Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101(5):1286–91.CrossRefPubMedGoogle Scholar
  20. 20.
    Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, et al. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014;23(3):158–65.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen MJ, Yeh YT, Lee KT, Tsai CJ, Lee HH, Wang SN. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol. 2012;106(2):181–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Nishihara T, Baba M, Matsuda M, Inoue M, Nishizawa Y, Fukuhara A, et al. Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. World J Gastroenterol. 2008;14(42):6473–80.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Sadik NA, Ahmed A, Ahmed S. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum Exp Toxicol. 2012;31(4):311–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Liu CJ, Chen PJ, Lai MY, Liu CH, Chen CL, Kao JH, et al. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol Int. 2009;3(2):364–70.CrossRefPubMedGoogle Scholar
  25. 25.
    Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology. 2010;139(5):1762–73. 73 e1-5.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010;52(5):1713–22.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Wang SN, Yang SF, Tsai HH, Lee KT, Yeh YT. Increased adiponectin associated with poor survival in hepatocellular carcinoma. J Gastroenterol. 2014;49(9):1342–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMedGoogle Scholar
  29. 29.
    Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–37.CrossRefPubMedGoogle Scholar
  30. 30.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMedGoogle Scholar
  31. 31.
    Bishop MJ, Plank G. Simulating photon scattering effects in structurally detailed ventricular models using a Monte Carlo approach. Front Physiol. 2014;5:338.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Song F, Gilbody S. Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ. 1998;316(7129):471.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMedGoogle Scholar
  34. 34.
    Sumie S, Kawaguchi T, Kuromatsu R, Takata A, Nakano M, Satani M, et al. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS One. 2011;6(11):e26840.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Khattab MA, Eslam M, Mousa YI, Ela-adawy N, Fathy S, Shatat M, et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann Hepatol. 2012;11(4):487–94.PubMedGoogle Scholar
  36. 36.
    Guo JW, Ma XB, Wang F, Liu M, Qi YZ, Wang ZG. The study of blood serum adiponectin levels and tumor relations. J Mod Oncol. 2012;20(10):2016–8.Google Scholar
  37. 37.
    Aleksandrova K, Boeing H, Nothlings U, Jenab M, Fedirko V, Kaaks R, et al. Inflammatory and metabolic biomarkers and risk of liver and bilary tract cancer. Hepatology. 2014.Google Scholar
  38. 38.
    Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6(4):459–64.CrossRefPubMedGoogle Scholar
  39. 39.
    Jonsson JR, Barrie HD, O’Rourke P, Clouston AD, Powell EE. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology. 2008;48(1):80–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547–94.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Gardener H, Crisby M, Sjoberg C, Hudson B, Goldberg R, Mendez AJ, et al. Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study. Metab Syndr Relat Disord. 2013;11(1):46–55.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007;18(3):263–70.CrossRefPubMedGoogle Scholar
  43. 43.
    Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol. 2009;34(2):339–44.PubMedGoogle Scholar
  44. 44.
    Clemmons DR. Insulin-like growth factor binding protein control secretion and mechanisms of action. Adv Exp Med Biol. 1991;293:113–23.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Intensive Care UnitJiangsu Province Nantong Tongzhou District People’s HospitalNantongChina
  2. 2.Department of OncologyJiangsu Province Nantong Tongzhou District People’s HospitalNantongChina

Personalised recommendations